<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC6156540/table_1" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 1</label>
  <p>Exemplary clinical trials employing viral vector based vaccines in the context of Ebola vaccine development.</p>
 </caption>
 <thead>
  <tr>
   <th valign="top" align="left" rowspan="1" colspan="1" id="0-0-.">
    <b>Study start</b>
   </th>
   <th valign="top" align="left" rowspan="1" colspan="1" id="0-1-.">
    <b>
     <i>N</i>
    </b>
   </th>
   <th valign="top" align="left" rowspan="1" colspan="1" id="0-2-.">
    <b>Vaccine and delivery</b>
   </th>
   <th valign="top" align="left" rowspan="1" colspan="1" id="0-3-.">
    <b>Outcome</b>
   </th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td valign="top" align="left" colspan="3" rowspan="1">
    <b>NCT00374309</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase I</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">Sept 2006</td>
   <td valign="top" align="left" rowspan="1" colspan="1">31</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Ad5</b> IM 
    <br/> 2 × 10 
    <sup>9</sup> or 2 × 10 
    <sup>10</sup> VP Antigen: GP EBOV and SUDV 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Safety:</b>
    <br/> Acceptable safety profile 
    <br/>
    <b>Immunogenicity:</b>
    <br/> - Antibody responses in 100% (SUDV GP) and 55% (EBOV GP) of subjects in the higher dose group- No significant induction of VNTs - T cell responses in 82% (SUDV GP) and 64% (EBOV GP) 
    <br/>
    <b>Of note:</b> Reduced immunogenicity in participants with pre-existing immunity against Ad5 
   </td>
  </tr>
  <tr style="border-top: thin solid #000000;">
   <td valign="top" align="left" colspan="3" rowspan="1">
    <b>NCT02326194</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase I</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">Dec 2014</td>
   <td valign="top" align="left" rowspan="1" colspan="1">120</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Ad5</b> IM 
    <br/> 4 × 10 
    <sup>10</sup> or 1.6 × 10 
    <sup>11</sup> VP Antigen: GP EBOV (2014) 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Safety</b>: No serious adverse events. 
    <br/>
    <b>Immunogenicity:</b>
    <br/>- Antibody responses in all but two participants (lower dose) and all (higher dose group) by d28 
    <br/>- Specific T cell responses (by ELISPOT and ICS); 
    <br/>
    <b>Of note:</b> high dose of Ad5 vector able to overcome negative effects of pre-existing immunity 
   </td>
  </tr>
  <tr style="border-top: thin solid #000000;">
   <td valign="top" align="left" colspan="3" rowspan="1">
    <b>NCT02575456</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase II</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">Oct 2015</td>
   <td valign="top" align="left" rowspan="1" colspan="1">500</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Ad5</b> IM 
    <br/> 8 × 10 
    <sup>10</sup> or 1.6 × 10 
    <sup>11</sup> VP Antigen: GP EBOV (2014) 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">Results not yet publicly available</td>
  </tr>
  <tr style="border-top: thin solid #000000;">
   <td valign="top" align="left" colspan="3" rowspan="1">
    <b>NCT02269423; NCT02280408</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase I</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">Oct 2014</td>
   <td valign="top" align="left" rowspan="1" colspan="1">78</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>VSV, attenuated</b>
    <br/> one or two doses IM 1 × 10 
    <sup>6</sup>, 2 × 10 
    <sup>7</sup> and 1 × 10 
    <sup>8</sup> PFU Antigen: GP EBOV (1995) 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Safety:</b>
    <br/> Mild adverse events, no cases of arthritis 
    <br/>
    <b>Immunogenicity:</b>
    <br/>- Antibody titers in all participants by day 28 
    <br/>- Increased levels of total and VNTs upon delivery of higher doses 
   </td>
  </tr>
  <tr style="border-top: thin solid #000000;">
   <td valign="top" align="left" colspan="3" rowspan="1">
    <b>NCT02231866; NCT02240875</b>
    <a ref-type="table-fn" rid="TN1">
     <sup>*</sup>
    </a>
    <b>; NCT02267109</b>
    <a ref-type="table-fn" rid="TN1">
     <sup>*</sup>
    </a>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase I</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">Aug 2014–Aug 2017</td>
   <td valign="top" align="left" rowspan="1" colspan="1">325</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>ChAd3, replication deficient</b>
    <br/> Single dose IM 1 × 10 
    <sup>10</sup>, 2.0 × 10 
    <sup>10</sup>, 2.5 × 10 
    <sup>10</sup>, 5 × 10 
    <sup>10</sup>, 1 × 10 
    <sup>11</sup>, 2.0 × 10 
    <sup>11</sup> VP Antigen: GP EBOV (1976) ± GP SUDV (1977) 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Safety:</b>
    <br/> Acceptable safety profile, mild to moderate adverse events. 
    <br/>
    <b>Immunogenicity:</b>
    <br/>- Antibody responses in almost all subjects; indications for durability (significant antibody titers detectable up to 48 weeks post vaccination) 
    <br/>- VNTs in some subjects 
    <br/>- Antigen-specific CD4 
    <sup>+</sup> and CD8 
    <sup>+</sup> T cells in some subjects 
    <br/>- Increased immune responses upon MVA boost 
   </td>
  </tr>
  <tr style="border-top: thin solid #000000;">
   <td valign="top" align="left" colspan="3" rowspan="1">
    <b>NCT02289027; NCT02344407</b>
    <a ref-type="table-fn" rid="TN2">
     <sup>**</sup>
    </a>
    <b>; (NCT02485301); (NCT02548078)</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase I/II</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">Oct 2014 
    <br/>- Nov 2015 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">5244</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>ChAd3, replication deficient</b>
    <br/> Single dose IM 2.5 × 10 
    <sup>10</sup>, 5 × 10 
    <sup>10</sup>, 1 × 10 
    <sup>11</sup> VP Antigen: GP EBOV (1976) 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Safety:</b>
    <br/> NCT02289027: Acceptable safety profile NCT02344407: serious adverse events within 12 months after inj. in 8.0% (40/500) of participants (9.4% in rVSV-ZEBOV) 
    <br/>
    <b>Immunogenicity:</b>
    <br/> NCT02289027 
    <br/>- Antibody responses peaked at d28 (51 μg/ml high dose group); still significantly over placebo at d180 (25.5 μg/ml) 
    <br/>- CD4 
    <sup>+</sup> and CD8 
    <sup>+</sup> T cell responses in 57% (28/49) and 67% NCT02344407 
    <br/>- Antibody responses in 70.8 and 63.5% of the participants at 1 and 12 months, respectively (83.7 and 79.5% for VSV-ZEBOV) 
   </td>
  </tr>
  <tr style="border-top: thin solid #000000;">
   <td valign="top" align="left" colspan="3" rowspan="1">
    <b>NCT02283099; NCT02296983; NCT02287480</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase I; Phase I/II</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">Nov 2014</td>
   <td valign="top" align="left" rowspan="1" colspan="1">158</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>VSV, attenuated</b>
    <br/> single dose IM 3 × 10 
    <sup>5</sup>, 3 × 10 
    <sup>6</sup>, 1 × 10 
    <sup>7</sup>, 2 × 10 
    <sup>7</sup>, 5 × 10 
    <sup>7</sup> PFU Antigen: GP EBOV (1995) 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Safety:</b>
    <br/> Doses of 1 × 10 
    <sup>7</sup> PFU or higher: 
    <br/>- Arthralgia in 22% (11/51) participants of Geneva cohort; arthritis confirmed in 9/ 11 cases; maculopapular rash in 27% (3/11) of these cases 
    <br/>- Self-limiting cases of arthritis in 3.4% (2/60) participants in Germany and Kenya cohort Dose of 3 × 10 
    <sup>5</sup> PFU: 
    <br/>- Reduced adverse events in mild to moderate range with arthralgia in 23% (13/56) participants 
    <br/>
    <b>Immunogenicity:</b>
    <br/>- Antibody responses in all subjects; persisted for 6 months 
    <br/>- Dose dep. VNTs in 85% (107/126) of vaccinees 
   </td>
  </tr>
  <tr style="border-top: thin solid #000000;">
   <td valign="top" align="left" colspan="3" rowspan="1">
    <b>NCT02378753</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase II/III</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">March 2015</td>
   <td valign="top" align="left" rowspan="1" colspan="1">7651</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>VSV, attenuated</b>
    <br/> single dose IM 2 × 10 
    <sup>7</sup> PFU Antigen: GP EBOV (1995) 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Safety:</b>
    <br/> Acceptable, one serious adverse event 
    <br/>
    <b>Immunogenicity:</b>
    <br/>- Ring vaccination approach; 48 clusters (4,123 people) and 42 clusters (3528 people) randomly assigned to immediate and delayed vaccination (21 days later) 
    <br/>- No cases of Ebola virus disease with symptom onset at least 10 days after randomization (immediate vaccination), 16 cases from seven clusters (delayed vaccination) 100% vaccination efficacy 
   </td>
  </tr>
 </tbody>
 <tfoot>
  <p>This table exclusively lists exemplary clinical trials discussed in the text. Ad5, Adenovirus 5; EBOV, Ebola virus; GP, Glycoprotein; ICS, intracellular staining; IM, intramuscular; N, number of study participants; PFU, Plaque Forming Unit; SUDV, Sudan virus; VNT, virus neutralization titers; VSV, vesicular stomatitis virus; VP, viral particles.</p>
  <p class="fn" charset="fn" id="TN1">
   <p class="label">*</p>
   <p>Boost with MVA based vaccine evaluated;</p>
  </p>
  <p class="fn" charset="fn" id="TN2">
   <p class="label">**</p>
   <p>
    <i>Direct comparison with rVSV-ZEBOV arm</i>. 
   </p>
  </p>
 </tfoot>
</table>
